Analysts Set Immuneering Corporation (NASDAQ:IMRX) PT at $16.50

Immuneering Corporation (NASDAQ:IMRX) has received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $16.50.

A number of research firms recently commented on IMRX. Chardan Capital reissued a “buy” rating and set a $20.00 target price on shares of Immuneering in a research report on Thursday, November 13th. Leerink Partners initiated coverage on Immuneering in a report on Friday, October 31st. They set an “outperform” rating and a $15.00 price objective for the company. Wall Street Zen cut Immuneering from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Mizuho set a $12.00 target price on Immuneering in a research report on Wednesday, October 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th.

Insider Activity at Immuneering

In related news, Director Peter Feinberg bought 20,000 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was bought at an average cost of $4.35 per share, for a total transaction of $87,000.00. Following the purchase, the director directly owned 135,441 shares of the company’s stock, valued at approximately $589,168.35. This trade represents a 17.32% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Thomas J. Schall bought 21,645 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were bought at an average cost of $4.67 per share, for a total transaction of $101,082.15. Following the transaction, the director owned 74,530 shares in the company, valued at $348,055.10. The trade was a 40.93% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 51,819 shares of company stock valued at $234,472 over the last ninety days. 22.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Immuneering

Hedge funds have recently made changes to their positions in the company. Sanofi acquired a new stake in Immuneering during the 3rd quarter worth about $18,960,000. Vanguard Group Inc. raised its stake in shares of Immuneering by 128.5% in the third quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock worth $16,907,000 after purchasing an additional 1,358,322 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Immuneering during the third quarter worth about $6,602,000. Blue Owl Capital Holdings LP purchased a new stake in Immuneering in the third quarter valued at approximately $3,850,000. Finally, Monashee Investment Management LLC purchased a new stake in Immuneering in the third quarter valued at approximately $2,100,000. 67.65% of the stock is owned by institutional investors and hedge funds.

Immuneering Price Performance

IMRX opened at $4.52 on Friday. The business’s 50-day moving average is $5.77 and its two-hundred day moving average is $5.87. Immuneering has a 1 year low of $1.10 and a 1 year high of $10.08. The firm has a market capitalization of $291.86 million, a PE ratio of -2.54 and a beta of 0.46.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). As a group, sell-side analysts expect that Immuneering will post -1.86 EPS for the current year.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.